LIA
PCRX icon

LS Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

LS Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,760
Closed -$264K – 575
2021
Q1 		$264K Sell
3,760
-165
-4% -$11.8K 0.01% 634
2020
Q4 		$235K Buy
+3,925
New +$230K 0.01% 754
2020
Q3 		– Sell
-1,437
Closed -$75K – 1259
2020
Q2 		$75K Buy
1,437
+117
+9% +$4.89K ﹤0.01% 1064
2020
Q1 		$44K Hold
1,320
– – ﹤0.01% 1139
2019
Q4 		$60K Hold
1,320
– – ﹤0.01% 1267
2019
Q3 		$50K Buy
+1,320
New +$52.7K ﹤0.01% 1302

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

LS Investment Advisors's PCRX Position: Q2 2021 in Review

LS Investment Advisors sold out of Pacira BioSciences (PCRX) in Q2 2021, closing a stake of 3,760 shares — an estimated $264K sold.

LS Investment Advisors first reported a position in PCRX in Q3 2019 and held it in 6 quarters. The position peaked at $264K in Q1 2021. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

  • LS Investment Advisors reported no remaining Pacira BioSciences position as of Q2 2021 after selling out during the quarter.
  • LS Investment Advisors sold 3,760 Pacira BioSciences shares in Q2 2021, an estimated $264K.
  • LS Investment Advisors first reported a position in Pacira BioSciences in Q3 2019 and held it in 6 quarters.
  • LS Investment Advisors's Pacira BioSciences position peaked at $264K in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on LS Investment Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.